On September 24, Agilent rose 5.2% in regular trading, trading at $173.91 per share, with turnover of $3.15 billion. The move came amid a broad rally across the Life Sciences Tools & Services sector.

Within the sector, individual stocks posted widespread gains, with Illumina up 8.11%, Tempus AI up 5.64%, IQVIA up 3.03%, Thermo Fisher Scientific up 2.43%, and Danaher up 1.28%. The sector-wide strength follows a period of improving fundamentals, as Agilent reported a strong fiscal Q3 earnings beat in late August, posting adjusted EPS of $1.62 versus the $1.49 consensus estimate, while revenue of $1.878 billion exceeded expectations of $1.841 billion. The company also raised its full-year guidance, now expecting revenue of $7.49 billion to $7.51 billion, above the prior Street estimate of $7.45 billion. Multiple analysts subsequently lifted price targets, including Baird to $180, Stifel to $180, and Morgan Stanley to $175, all maintaining bullish ratings. The stock has also been supported by recent product milestones, including the FDA-cleared S540MD slide scanner launch and expanded PD-L1 diagnostic approvals.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)